Xeris Biopharma (NASDAQ:XERS) Insider Sells $101,002.02 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $6.06, for a total transaction of $101,002.02. Following the transaction, the insider owned 1,176,506 shares in the company, valued at $7,129,626.36. The trade was a 1.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Friday, May 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $6.23, for a total transaction of $103,835.41.
• On Wednesday, April 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $5.99, for a total transaction of $99,835.33.

Xeris Biopharma Trading Up 4.4%

Shares of Xeris Biopharma stock opened at $6.15 on Friday. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. Xeris Biopharma Holdings, Inc. has a 12-month low of $4.30 and a 12-month high of $10.08. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of 102.50 and a beta of 0.78. The firm’s 50 day simple moving average is $6.08 and its two-hundred day simple moving average is $6.60.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The business had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Institutional Trading of Xeris Biopharma

Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after acquiring an additional 1,358,760 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Xeris Biopharma by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock valued at $33,571,000 after acquiring an additional 135,815 shares during the last quarter. State Street Corp boosted its holdings in shares of Xeris Biopharma by 10.1% in the 4th quarter. State Street Corp now owns 4,116,924 shares of the company’s stock valued at $32,318,000 after acquiring an additional 378,595 shares during the last quarter. Qube Research & Technologies Ltd boosted its holdings in Xeris Biopharma by 6.0% during the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock worth $26,657,000 after buying an additional 185,063 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after buying an additional 1,199,435 shares in the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on XERS shares. Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a report on Monday, March 2nd. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.